1. PWE-020 Corticosteroid Dose Reduction with Vedolizumab Treatment of Crohn's Disease. (17th August 2016) Authors: Loftus, E; Siegel, C; Panaccione, R; Sandborn, W; Smyth, M; James, A; Xu, J; Abhyankar, B Journal: Gut Issue: Volume 65(2016)Supplement 1 Page Start: A147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 756 'predicted sickness absence from employment compared with department of social protection guidelines for closed certification with common health problems'. (24th April 2018) Authors: Kononenko, N; Loftus, E; Whelan, D Journal: Occupational and environmental medicine Issue: Volume 75(2018)Supplement 2 Page Start: A75 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PTH-072 Corticosteroid Dose Reduction in Ulcerative Colitis Patients Treated with Vedolizumab. (17th August 2016) Authors: Loftus, E; Siegel, C; Panaccione, R; Sandborn, W; Smyth, M; James, A; Xu, J; Abhyankar, B Journal: Gut Issue: Volume 65(2016)Supplement 1 Page Start: A254 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. DOP38 Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1. (21st January 2022) Authors: Vermeire, S; Colombel, J F; Takeuchi, K; Gao, X; Panaccione, R; Danese, S; Dubinsky, M; Schreiber, S; Ilo, D; Finney-Hayward, T; Zhou, W; Phillips, C; Yao, X; Zhou, Q; Loftus, E Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i087 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A145 EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY. (21st February 2022) Authors: Panaccione, R; Danese, S; Zhouwen, W; Pangan, A; Hébuterne, X; Nakase, H; D'Haens, G; Panes, J; Lindsay, J; Higgins, P; Loftus, E; Sandborn, W; Xie, W; Sanchez gonzalez, Y; Liu, J; Weinreich, M; Vermeire, S Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 5(2022)Supplement 1 Page Start: 18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus. (July 2022) Authors: Ananthakrishnan, Ashwin N; Kaplan, Gilaad G; Bernstein, Charles N; Burke, Kristin E; Lochhead, Paul J; Sasson, Alexa N; Agrawal, Manasi; Tiong, Jimmy Ho Tuan; Steinberg, Joshua; Kruis, Wolfgang; Steinwurz, Flavio; Ahuja, Vineet; Ng, Siew C; Rubin, David T; Colombel, Jean-Frederic; Gearry, Richard... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 7(2022) Page Start: 666 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P325 Real-World Effectiveness And Safety Of Ustekinumab In Patients With Ulcerative Colitis: A Multi-Centre Study. (27th May 2021) Authors: Parakkal, D; Johnson, A; Fenster, M; Ramos, G; Zulqarnain, M; Ullman, T; Huang, L; Gutierrez, A; Bruss, A; Ungaro, R; Cohen, B; Gaurav, S; Anish, P; Sasankan, P; Costable, N; Pekow, J; Wang, W; Rubin, D; Ciorba, M; Beniwal-Patel, P Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S349 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. DOP82 Corticosteroid-free remission of Ulcerative Colitis with filgotinib maintenance therapy: Post hoc analysis of the phase 2b/3 SELECTION study. (27th May 2021) Authors: Loftus, E; Vermeire, S; Feagan, B; Yun, C; Hsieh, J; Liu, X; Zhao, S; Moerch, U; Sandborn, W J; Hibi, T Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S112 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P271 Evolving Targets in Ulcerative colitis: Defining Disease Clearance in the VARSITY Study. (27th May 2021) Authors: Danese, S; Schreiber, S; Loftus, E; Colombel, J F; Peyrin-Biroulet, L; Agboton, C; Lindner, D; Lirio, R; Sands, B Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S305 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P631 Long-term safety of vedolizumab versus other biologic agents in ulcerative colitis (UC) and Crohn's Disease (CD): Results from a large multinational prospective observational study. (30th January 2023) Authors: Louis, E; Sebastien, S; Siegmund, B; Bossuyt, P; Danese, S; de Boer, N; Loftus, E; Moum, B; Peyrin-Biroulet, L; Schreiber, S; Zhou, J; Wernicke, J; Angellotti, E; Siegel, C Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i762 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗